Hims & Hers Health, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andrew Dudum
- Full Time Employees
- 2,442
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 2269 Chestnut Street San Francisco CA United States 94123
- IPO Date
- Sep 9, 2019
- CIK
- 0001773751
- Website
- hims.com
- Similar Companies
- Business
- Hims & Hers Health, Inc. operates a telehealth platform providing direct-to-consumer healthcare services and products primarily across the United States, the United Kingdom, and select European markets, with plans for further global expansion. The company offers a comprehensive range of core products and services including prescription medications, over-the-counter drugs, and personal care products under its consumer-facing brands Hims (targeting men) and Hers (targeting women). Key product categories encompass sexual health treatments such as erectile dysfunction medications and birth control; hair care products including hair loss treatments; mental health services including therapy and coaching; weight loss programs integrating medication; skincare products; and preventive health solutions. The platform connects customers with licensed healthcare providers who deliver personalized treatment plans through virtual consultations, often asynchronously, supported by ongoing clinical care and educational resources. Hims & Hers also operates vertically integrated pharmacy fulfillment facilities alongside partnerships with external pharmacies for prescription delivery. Founded in 2017 and headquartered in San Francisco, California, Hims & Hers has rapidly evolved from focusing initially on men's health and stigmatized conditions like erectile dysfunction to a broad telehealth ecosystem covering multiple specialties and wellness areas for both men and women. Recent major developments include the acquisition of YourBio Health, which brings advanced pain-free blood sampling technology to enhance diagnostic services, and the strategic acquisition of ZAVA, a leading European digital health platform, which expands Hims & Hers’ footprint into the UK, Germany, France, and Ireland with plans to further penetrate European markets. The company also announced a significant collaboration with Novo Nordisk to expand affordable access to obesity care, alongside launching AI-powered tools like MedMatch to personalize treatment plans using large-scale data analytics. Additionally, Hims & Hers initiated a $250 million share repurchase program in 2025 and planned a market entry into Canada timed with availability of generic weight loss medication semaglutide. Hims & Hers operates within the broader healthcare and biotechnology sectors and targets adult consumers seeking accessible, affordable, and stigma-free telehealth services and products. Its business model integrates telemedicine consultations, electronic medical records, cloud-based pharmacy fulfillment, and personalized healthcare technology. With over 2.4 million subscribers as of mid-2025, the company has scaled its operations nation-wide in the US and strategically expanded internationally through acquisitions and partnerships with major health systems like Ochsner, Mount Sinai, and Hartford Healthcare to enhance continuity of care that bridges digital and in-person services. The firm's continuous innovation and targeted market expansion position it as a growing leader in global digital health and wellness delivery.
Company News
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (HIMS) of the Deadline to Seek Lead Plaintiff Status on November 2, 2026
Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Consensus Target Price of $32.43
HIMS DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS
INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline - HIMS
HIMS 12-DAY DEADLINE ALERT: Hims & Hers Health Faces Securities Fraud Class Action, Investors with Losses Encouraged to Contact Hagens Berman
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to an Upcoming Deadline of November 2, 2026 in the Securities Class Action
HIMS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Hims (HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men's Health Launch to Date
Kaplan Fox Notifies Investors: Hims & Hers Health, Inc. (HIMS) Faces a Securities Class Action With a November 2, 2026 Deadline
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
HIMS DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS
Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, Inc. Investors of the Upcoming Lead Plaintiff Deadline and Urges Investors to Contact the Firm Before November 2nd
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines – HIMS
Hims & Hers stock rises 5% as company launches men's weight care in Germany
What's Next for Hims & Hers Health, Inc. Shareholders After 14.73% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
DEADLINE ALERT for YSS, HIMS, UNCY, and PZZA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Hims & Hers Health (NYSE: HIMS) Facing Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower
Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors With Significant Losses to Take Action Before the November 2, 2026 Lead Plaintiff Deadline
Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm Before November 2, 2026, for Information About Leading the Lawsuit Against Hims & Hers
HIMS DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS